{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:31:08Z","timestamp":1703809868960},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with chronic hepatitis B (CHB) are regularly monitored for HBV DNA and liver enzymes in order to assess disease progression and the need for antiviral therapy. Identifying patients with a stable course of disease can potentially prolong the intervals between visits, withhold unnecessary tests and save money. Accordingly, we aimed to find predictors for a stable disease course in patients with CHB. 579 patients with CHB, who were followed in a tertiary referral center between January 2004\u2013December 2018, were retrospectively analyzed. Patients with low and steady viral load titer (&lt;\u20092000 IU\/ml) and normal ALT levels (&lt;\u200940 IU\/ml) in 6 consecutive clinic encounters were considered to have a stable course of CHB. A stepwise multivariate logistic regression analysis and a decision tree model were used to identify predictors of a stable disease course. Following exclusion of ineligible patients, a total of 220 patients were included in the final analysis. 64\/220 patients had a stable disease course. Patients with a stable disease were older (62.99\u2009\u00b1\u200912.36 Vs. 54.07\u2009\u00b1\u200913.64, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) with a higher percentage of women (53% vs. 38%) and had lower baseline levels of AST, ALT and viral load (VL). In a multivariate analysis, age (OR 0.94, 95% CI 0.91\u20130.98), baseline ALT (OR 1.06, 95% CI 1.01\u20131.1) and VL (OR 1.05 95% CI 1.02\u20131.08), were significantly associated with a stable disease. In a decision tree model, patients 46\u201367 years old, with baseline VL\u2009&lt;\u2009149 IU\/mL and ALT\u2009&lt;\u200940 IU\/mL had the best probability (91%) for a stable disease course over 4.4\u2009\u00b1\u20092.2 years. We conclude that integrating patients\u2019 age with baseline VL and ALT can predict a stable disease course in patients with CHB off treatment.<\/jats:p>","DOI":"10.1038\/s41598-023-50460-2","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T14:02:29Z","timestamp":1703772149000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A decision-making model for prediction of a stable disease course in chronic hepatitis B patients"],"prefix":"10.1038","volume":"13","author":[{"given":"Imri","family":"Ofri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noam","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Leshno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Shlomai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"50460_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/jvh.13452","volume":"28","author":"C Campbell","year":"2021","unstructured":"Campbell, C., Wang, T., McNaughton, A. L., Barnes, E. & Matthews, P. C. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: A systematic review and meta-analysis. J. Viral. Hepat. 28, 493\u2013507 (2021).","journal-title":"J. Viral. Hepat."},{"key":"50460_CR2","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMra0801644","volume":"359","author":"JL Dienstag","year":"2008","unstructured":"Dienstag, J. L. & Hepatitis, B. Virus infection. New Eng. J. Med. 359, 1486\u20131500 (2008).","journal-title":"New Eng. J. Med."},{"key":"50460_CR3","unstructured":"Alaluf MB, Shlomai A. New therapies for chronic hepatitis B. Liver International 2016."},{"key":"50460_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/apt.15581","volume":"51","author":"EJ Smolders","year":"2020","unstructured":"Smolders, E. J., Burger, D. M., Feld, J. J. & Kiser, J. J. Review article: Clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment. Pharmacol. Ther. 51, 231\u2013243 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"50460_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico, P. et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398 (2017).","journal-title":"J. Hepatol."},{"key":"50460_CR6","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560\u20131599 (2018).","journal-title":"Hepatology"},{"key":"50460_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"C Chen","year":"2006","unstructured":"Chen, C. et al. RIsk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus Dna level. JAMA 295, 65\u201373 (2006).","journal-title":"JAMA"},{"key":"50460_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","volume":"62","author":"GV Papatheodoridis","year":"2015","unstructured":"Papatheodoridis, G. V., Chan, H. L., Hansen, B. E., Janssen, H. L. & Lampertico, P. Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. J. Hepatol. 62, 956\u2013967 (2015).","journal-title":"J. Hepatol."},{"key":"50460_CR9","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GL-H Wong","year":"2013","unstructured":"Wong, G.L.-H. et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. Hepatology 58, 1537\u20131547 (2013).","journal-title":"Hepatology"},{"key":"50460_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jhep.2021.08.019","volume":"76","author":"Q Ye","year":"2022","unstructured":"Ye, Q. et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J. Hepatol. 76, 63\u201374 (2022).","journal-title":"J. Hepatol."},{"key":"50460_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/liv.14365","volume":"40","author":"DQ Huang","year":"2020","unstructured":"Huang, D. Q. & Lim, S. G. Hepatitis B: Who to treat? A critical review of international guidelines. Liver Int. 40, 5\u201314 (2020).","journal-title":"Liver Int."},{"issue":"Suppl 1","key":"50460_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/liv.13006","volume":"36","author":"F Invernizzi","year":"2016","unstructured":"Invernizzi, F., Vigan\u00f2, M., Grossi, G. & Lampertico, P. The prognosis and management of inactive HBV carriers. Liver Int 36(Suppl 1), 100\u2013104 (2016).","journal-title":"Liver Int"},{"key":"50460_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/gut.2007.128496","volume":"57","author":"G Fattovich","year":"2008","unstructured":"Fattovich, G. et al. Long-term outcome of chronic hepatitis B in Caucasian patients: Mortality after 25 years. Gut 57, 84\u201390 (2008).","journal-title":"Gut"},{"key":"50460_CR14","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","volume":"35","author":"YS Hsu","year":"2002","unstructured":"Hsu, Y. S. et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35, 1522\u20131527 (2002).","journal-title":"Hepatology"},{"key":"50460_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1053\/j.gastro.2004.06.021","volume":"127","author":"M Manno","year":"2004","unstructured":"Manno, M. et al. Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years. Gastroenterology 127, 756\u2013763 (2004).","journal-title":"Gastroenterology"},{"key":"50460_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jmv.20434","volume":"77","author":"GH Zacharakis","year":"2005","unstructured":"Zacharakis, G. H. et al. Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II\/EC-project). J. Med. Virol. 77, 173\u2013179 (2005).","journal-title":"J. Med. Virol."},{"key":"50460_CR17","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/0016-5085(94)90760-9","volume":"106","author":"JP Villeneuve","year":"1994","unstructured":"Villeneuve, J. P. et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 106, 1000\u20131005 (1994).","journal-title":"Gastroenterology"},{"key":"50460_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2893.2007.00957.x","volume":"15","author":"GV Papatheodoridis","year":"2008","unstructured":"Papatheodoridis, G. V., Chrysanthos, N., Hadziyannis, E., Cholongitas, E. & Manesis, E. K. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J. Viral. Hepat. 15, 434\u2013441 (2008).","journal-title":"J. Viral. Hepat."},{"key":"50460_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/CMR.00046-19","volume":"33","author":"MH Nguyen","year":"2020","unstructured":"Nguyen, M. H., Wong, G., Gane, E., Kao, J. H. & Dusheiko, G. Hepatitis B virus: Advances in prevention, diagnosis, and therapy. Clin. Microbiol. Rev. 33, 10\u20131128 (2020).","journal-title":"Clin. Microbiol. Rev."},{"key":"50460_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clim.2018.04.002","volume":"196","author":"D Ray","year":"2018","unstructured":"Ray, D. & Yung, R. Immune senescence, epigenetics and autoimmunity. Clin. Immunol. 196, 59\u201363 (2018).","journal-title":"Clin. Immunol."},{"key":"50460_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jim.2018.08.005","volume":"463","author":"AA Sadighi Akha","year":"2018","unstructured":"Sadighi Akha, A. A. Aging and the immune system: An overview. J. Immunol. Methods 463, 21\u201326 (2018).","journal-title":"J. Immunol. Methods"},{"issue":"Suppl 1","key":"50460_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn, K. A., Petrick, J. L. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma. Hepatology 73(Suppl 1), 4\u201313 (2021).","journal-title":"Hepatology"},{"key":"50460_CR23","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s10620-019-05537-2","volume":"64","author":"M Sayiner","year":"2019","unstructured":"Sayiner, M., Golabi, P. & Younossi, Z. M. Disease burden of hepatocellular carcinoma: A global perspective. Dig. Dis. Sci. 64, 910\u2013917 (2019).","journal-title":"Dig. Dis. Sci."},{"key":"50460_CR24","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/jgh.12934","volume":"30","author":"S-H Wang","year":"2015","unstructured":"Wang, S.-H., Chen, P.-J. & Yeh, S.-H. Gender disparity in chronic hepatitis B: Mechanisms of sex hormones. J. Gastroenterol. Hepatol. 30, 1237\u20131245 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"50460_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","volume":"1","author":"N Peleg","year":"2019","unstructured":"Peleg, N. et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Rep. 1, 9\u201316 (2019).","journal-title":"JHEP Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50460-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T14:12:26Z","timestamp":1703772746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50460-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["50460"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50460-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]},"assertion":[{"value":"29 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23051"}}